MEK Inhibitor Tocriset™
Cat. No. 2243
Contents of Tocriset:
Product Name / Activity
|potent, selective inhibitor of MEK1 and MEK2|
|specific inhibitor of MAPKK/MEK|
|selective inhibitor of MEK1 and MEK2; brain penetrant|
Biological ActivityContains the above products which can be used to selectively inhibit MEK signalling. The products are supplied either as a solid (U0126) or pre-dissolved in DMSO at a stock concentration of 10 mM in 0.5 ml.
Tocrisets contain 3-5 ligands supplied as lyophilized solids or pre-dissolved in DMSO at a specified concentration. Lyophilized solids have been freeze-dried (approximately 0.5-2 mg per vial) so that addition of 0.5 or 1 ml of solvent produces a stock concentration of 10 or 5 mM respectively.
Please see individual product listings for specific technical data and certificate of analysis.
Product Data Sheet / Safety Data Sheet
ReferencesPlease see individual product listings for specific references.
View Related Products by Target
Keywords: MEK Inhibitor Tocriset, supplier, MEK, Inhibitor, Tocriset
Find multiple products by catalog number
New Products in this Area
Cyclin-dependent kinase inhibitorGSK2578215A
Potent, selective LRRK2 inhibitor; brain penetrantAmlexanox
Inhibitor of TBK1 and IKKε; antiallergic agentPF 05212384
Potent and selective dual PI 3-kinase/mTOR inhibitorPF 03814735
Aurora kinase A and B inhibitorPF 04691502
Dual PI 3-K/mTOR inhibitorTNP
Inhibitor of IP6K; also inhibits IP3KACHP
Selective IKKα and IKKβ inhibitorPD 0332991 isethionate
Potent, selective Cdk4/6 inhibitor; brain penetrantCZC 24832
Selective inhibitor of PI 3-Kinase γLY 333531 hydrochloride
Protein kinase C inhibitor; selective for β isozymesPF 06465469
Potent inhibitor of interleukin-2 inducible T cell kinase (ITK). Also inhibits BTK10Z-Hymenialdisine
Pan kinase inhibitor; potently inhibits MEK-1CP 690550 citrate
Potent JAK inhibitorWYE 687 dihydrochloride
Potent and selective mTOR inhibitorN,N-Dimethylsphingosine
Sphingosine kinase inhibitorPEP 005
Protein kinase C activatorCZC 54252 hydrochloride
Potent LRRK2 inhibitor; neuroprotectiveBisindolylmaleimide II
Potent PKC inhibitor and nicotinic receptor antagonistCID 2011756
Pan protein kinase D (PKD) inhibitor; cell permeable
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.